ACTL6B

Across TCGA pan-cancer cohorts, ACTL6B Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ACTL6B data layer compared with 22 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ACTL6B Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated ACTL6B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, SKCM, and MESO are the cancer types where ACTL6B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	1.000	0.627	.010	26	view →
SKCM	DFS	Median	III,IV	0.064	0.602	<.001	15	view →
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ACTL6B–UCEC (DFS)

Open the UCEC breakdown →